Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3574840 | 0.80 | KCNA5 (0.45) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL18779167 | 0.78 | KCNA5 (0.47) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL28632031 | 0.71 | KCNA5 (0.50) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL18193367 | 0.71 | KCNA5 (0.50) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL11631301 | 0.70 | KCNA5 (0.43) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL5929605 | 0.70 | CYP1A2 (0.53) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14698924 | 0.70 | KCNA5 (0.49) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL7818392 | 0.69 | CNR1 (0.48) | LMNACNR1 | |
| SCHEMBL11628019 | 0.68 | KCNA5 (0.47) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL12238648 | 0.68 | CYP3A4 (0.49) | CYP3A4LMNACYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| EP-1891038-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124447-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | AR, FSHR, SHBG | CYP3A4 804/4885LMNA 3854/4885CYP1A2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.